GET DAILY SIGNALSAbbVie (ABBV) and the +12% Path Toward a $325 Target
Key Takeaways
- The central target of $325 is the arithmetic mean of verified analyst price targets above the current price, not an official published consensus.
- At roughly $291 per share, reaching $325 would require about a 12% gain — a modest but meaningful move for a stock of this size.
- The overall average across all tracked analyst targets is near $307–$310, with a wide range from roughly $237 to $350, reflecting real disagreement on valuation.
- Key supports include strong growth from Skyrizi and Rinvoq, raised full-year guidance, and a broadening immunology and oncology pipeline.
- Principal risks are biosimilar competition, a still-soft aesthetics segment, and a premium valuation after a strong run.
- For more on AbbVie's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for the latest updates.
- To see how AI applies these signals across the market, explore Trending AI Robots.
Analyst Targets and the Broader Consensus
Roughly 29 analysts tracked by S&P Global cover AbbVie, with a consensus rating of Buy and an overall average price target near $310.65. Yahoo Finance lists a one-year target estimate of about $306.42, while the full range spans from roughly $237 to $350. Because the overall mean sits only about 6% above the current price — below the threshold needed for a meaningful target — the $325 figure used here is the average of the individual targets that sit above the current share price.
Recent post-earnings revisions illustrate how analysts are thinking. Following third-quarter results, DZ Bank lifted its target to $345 (Nov. 5), Argus to $320 (Nov. 6), and Freedom Broker to $315 (Nov. 4). Earlier in the week, BMO Capital set $340, Cantor Fitzgerald and Leerink Partners set $325, and Guggenheim set $322. Morgan Stanley and Wells Fargo moved to roughly $346 and $340, respectively, while RBC Capital went to $330 and Canaccord Genuity to $338. The average of these above-price targets is about $326, rounded to $325. The dispersion — from the high-$290s to the mid-$340s — reflects differing views on how much multiple expansion AbbVie's growth justifies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
AbbVie closed near $291 on Nov. 6, 2026, with a market capitalization of roughly $515 billion. Reaching $325 implies upside of about 12%, a modest move for a large-cap pharmaceutical name that has already gained more than 30% over the trailing year. The stock trades just below its 52-week range of roughly $191 to $303.
The path toward the target runs through execution, not headline catalysts alone. Third-quarter revenue rose about 10% to $17.4 billion, with the immunology segment up 16% to $9.2 billion. Management raised full-year revenue guidance by $200 million to $67.8 billion and lifted the midpoint of adjusted EPS guidance to about $13.97. Sustained double-digit growth from Skyrizi and Rinvoq, which are absorbing the decline of legacy blockbuster Humira, is the core driver analysts cite for higher targets.
What Could Support a Move Toward the Target
The strongest support is the successful transition from Humira to next-generation immunology drugs. Skyrizi and Rinvoq continue to add new indications and formulations, and newer assets including Ententamig, Epkinly, and Juvmo — the latter receiving FDA approval in the quarter for Parkinson's disease — broaden the revenue base. The 2026 acquisition of Apogee deepens AbbVie's immunology pipeline. Combined with a beta near 0.2 and a forward dividend yield of about 2.4%, the stock has also benefited from rotation into defensive sectors. Analysts who raised targets generally cite these fundamentals and improved guidance.
What Could Prevent the Target From Being Reached
Valuation is the principal obstacle. AbbVie trades at a forward P/E premium to many large-cap pharmaceutical peers, meaning any slowdown in Skyrizi or Rinvoq prescription growth could trigger multiple compression. Biosimilar competition, particularly as Humira erosion continues and new entrants target growth products, remains a structural risk. The aesthetics segment, including Botox, has been soft, and acquisitions have added debt and interest expense. If core-product growth moderates or the defensive rotation reverses, the stock could consolidate below the $325 level even if earnings stay on track.
Technical Levels and Market Structure
AbbVie trades near the top of its 52-week range of about $191 to $303, so the $300 mark is a psychological level that bulls need to clear and hold before a push toward $325 becomes viable. The area near the 52-week high around $303 stands as near-term resistance, while the long-term uptrend remains intact given the stock's multi-year advance. A decisive move above the prior high would put $325 within reach as the next logical extension; a failure there could leave the shares range-bound.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary. Investors weighing the path to $325 should watch quarterly immunology sales, Skyrizi and Rinvoq prescription trends, guidance updates, and the timing of new indication approvals. Valuation multiples relative to peers, interest-rate decisions that influence defensive flows, and any developments on biosimilar competition for growth products are also important. No single data point will resolve the question; the trajectory of core-product growth and the market's willingness to pay for it will.
Final Assessment
The $325 target represents the average of analyst price targets above AbbVie's current price, implying about a 12% move. The case rests on the successful Skyrizi-Rinvoq transition, raised guidance, and a deepening pipeline, while the risks center on valuation, biosimilar competition, and a lagging aesthetics business. Analysts genuinely disagree, with targets spanning from the high-$290s to the mid-$340s, so $325 is a reasonable midpoint of bullish expectations rather than a consensus guarantee. Whether the stock reaches that level will depend on sustained core-product growth and the multiple investors are willing to assign it — outcomes no one can predict with certainty.
Using Tickeron’s AI Daily Buy/Sell Signals in Practice
In my research process, I often review Tickeron’s AI Daily Buy/Sell Signals to monitor how technical and market conditions align with the fundamental picture for names like AbbVie. The tool applies artificial intelligence across thousands of securities to flag Buy, Sell, or Hold signals, helping add a timely, data-driven perspective without replacing core analysis. It has become a regular part of how I cross-check opportunities and track shifts in real time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABBV saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.360). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.695). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement